CXCL8 and neoplasm: Growing evidence has highlighted the close association between high levels of IL-8, EVs production, NETosis, and limited therapeutic response in a variety of malignancies, thus paving the way to investigations on the therapeutic potential of combination treatments either of IL-8 activity blockers, or anti-EVs drugs, or NETosis inhibitors with standard antitumoral therapies, to reduce or counteract tumor drug resistance (162, 193).